These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 28663576)

  • 1. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.
    Martinelli G; Mancini M; De Benedittis C; Rondoni M; Papayannidis C; Manfrini M; Meggendorfer M; Calogero R; Guadagnuolo V; Fontana MC; Bavaro L; Padella A; Zago E; Pagano L; Zanotti R; Scaffidi L; Specchia G; Albano F; Merante S; Elena C; Savini P; Gangemi D; Tosi P; Ciceri F; Poletti G; Riccioni L; Morigi F; Delledonne M; Haferlach T; Cavo M; Valent P; Soverini S
    Leukemia; 2018 Jan; 32(1):139-148. PubMed ID: 28663576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.
    Mancini M; Monaldi C; De Santis S; Papayannidis C; Rondoni M; Sartor C; Bruno S; Pagano L; Criscuolo M; Zanotti R; Bonifacio M; Tosi P; Arock M; Valent P; Cavo M; Soverini S
    Biomark Res; 2023 Mar; 11(1):29. PubMed ID: 36894973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
    Aichberger KJ; Mayerhofer M; Gleixner KV; Krauth MT; Gruze A; Pickl WF; Wacheck V; Selzer E; Müllauer L; Agis H; Sillaber C; Valent P
    Blood; 2007 Apr; 109(7):3031-41. PubMed ID: 17110460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
    Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
    Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
    Fontebasso AM; Schwartzentruber J; Khuong-Quang DA; Liu XY; Sturm D; Korshunov A; Jones DT; Witt H; Kool M; Albrecht S; Fleming A; Hadjadj D; Busche S; Lepage P; Montpetit A; Staffa A; Gerges N; Zakrzewska M; Zakrzewski K; Liberski PP; Hauser P; Garami M; Klekner A; Bognar L; Zadeh G; Faury D; Pfister SM; Jabado N; Majewski J
    Acta Neuropathol; 2013 May; 125(5):659-69. PubMed ID: 23417712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
    Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
    ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SETD2 reduction adversely affects the development of mouse early embryos.
    Li C; Huang Z; Gu L
    J Cell Biochem; 2020 Jan; 121(1):797-803. PubMed ID: 31407364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy.
    Martelli M; Monaldi C; De Santis S; Bruno S; Mancini M; Cavo M; Soverini S
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32498255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
    Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
    Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
    Sly N; Gaspar K
    Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence specificity analysis of the SETD2 protein lysine methyltransferase and discovery of a SETD2 super-substrate.
    Schuhmacher MK; Beldar S; Khella MS; Bröhm A; Ludwig J; Tempel W; Weirich S; Min J; Jeltsch A
    Commun Biol; 2020 Sep; 3(1):511. PubMed ID: 32939018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPOP-containing complex regulates SETD2 stability and H3K36me3-coupled alternative splicing.
    Zhu K; Lei PJ; Ju LG; Wang X; Huang K; Yang B; Shao C; Zhu Y; Wei G; Fu XD; Li L; Wu M
    Nucleic Acids Res; 2017 Jan; 45(1):92-105. PubMed ID: 27614073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SETD2 histone modifier loss in aggressive GI stromal tumours.
    Huang KK; McPherson JR; Tay ST; Das K; Tan IB; Ng CC; Chia NY; Zhang SL; Myint SS; Hu L; Rajasegaran V; Huang D; Loh JL; Gan A; Sairi AN; Sam XX; Dominguez LT; Lee M; Soo KC; Ooi LL; Ong HS; Chung A; Chow PK; Wong WK; Selvarajan S; Ong CK; Lim KH; Nandi T; Rozen S; Teh BT; Quek R; Tan P
    Gut; 2016 Dec; 65(12):1960-1972. PubMed ID: 26338826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
    Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
    Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
    Peter B; Bibi S; Eisenwort G; Wingelhofer B; Berger D; Stefanzl G; Blatt K; Herrmann H; Hadzijusufovic E; Hoermann G; Hoffmann T; Schwaab J; Jawhar M; Willmann M; Sperr WR; Zuber J; Sotlar K; Horny HP; Moriggl R; Reiter A; Arock M; Valent P
    Leukemia; 2018 Apr; 32(4):1016-1022. PubMed ID: 29249817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
    Singh A; Al-Kali A; Begna KH; Litzow MR; Larsen JT; Sher T; Abdelmagid MG; Farrukh F; Reichard KK; Gangat N; Pardanani A; Tefferi A
    Am J Hematol; 2022 May; 97(5):630-637. PubMed ID: 35156231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
    DeAngelo DJ; George TI; Linder A; Langford C; Perkins C; Ma J; Westervelt P; Merker JD; Berube C; Coutre S; Liedtke M; Medeiros B; Sternberg D; Dutreix C; Ruffie PA; Corless C; Graubert TJ; Gotlib J
    Leukemia; 2018 Feb; 32(2):470-478. PubMed ID: 28744009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.